Karen Massey

Chief Executive Officer and Executive Director, argenx SE

Search every verified Karen Massey interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Karen Massey, who became CEO and Executive Director of Argenx in 2026 after joining as COO in 2023, has discussed the company's strategy and leadership approach in recent interviews. In a June 2026 podcast with Trends, she addressed topics including drug pricing and reimbursement, stating that the cost of medicines varies by market and that Argenx focuses on demonstrating the value its products bring to healthcare systems. She also noted the company has maintained a narrow price band between the U.S. and the rest of the world for Vyvgart, which she said limits exposure, and expressed a desire to shorten the time between drug approval and reimbursement through collaboration with governments. Massey welcomed competition in the biotech sector, saying it drives innovation and better outcomes for patients, and outlined a vision for Argenx beyond its current focus on Vyvgart and FcRn, describing a future portfolio of products across immunology diseases. In an earlier March 2026 podcast with Kinara, Massey emphasized the importance of scaling innovation and fostering a culture that supports it. She said breakthrough ideas do not come from average thinking and that organizations must actively fight against consensus. She criticized hierarchy and bureaucracy as obstacles to innovation, arguing that risk-averse leadership often stifles creativity as companies grow. Massey also discussed the need for clear decision-making models, noting that authoritative structures can lead to decisions based on poor information, and highlighted the value of in-person collaboration, describing office spaces as investments in innovation rather than expenses.